Skip to content

Author

D. Muramatsu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Real-Time Single Molecule Imaging Reveals Pathway-Selective Action of Aducanumab on Amyloid-β Aggregation.

Aducanumab is an anti-amyloid-β (Aβ) antibody that binds aggregated Aβ species and has been reported to inhibit secondary nucleation on fibril surfaces. However, how antibody binding influences aggregate dynamics at the molecular level remains incompletely understood. Here, we used high-speed atomic force microscopy (H...

T. Watanabe-Nakayama, M. Noguchi-Shinohara, Kenichi Umeda et al. · 0 citations
Open access Aug 2026

Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181

It is suggested that integrating CSF-ptau181 measurement and baseline MRI into clinical decision-making may support individualized risk stratification and the safe, sustained use of lecanemab in real-world practice.

M. Noguchi-Shinohara, D. Muramatsu, Ayano Shima et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.